Further Clinical Evidence

RNS Number : 0969K
Advanced Medical Solutions Grp PLC
11 July 2011

For Release: 11 July 2011




Advanced Medical Solutions Group plc



Further Evidence in Support of AMS Antimicrobial Products


Advanced woundcare dressing effective against 160 different types of

Chronic and Burn Wound Microorganisms, including 29 strains of MRSA 


Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces that, as part of the continued support to its global business partners, two further clinical studies have recently been published, targeted to help drive continued growth in AMS’s key silver alginate woundcare business.


The studies, which were published in both The International Wound Journal and the Journal of Woundcare, demonstrate the antimicrobial efficacy of one of AMS’s commercialised silver alginate dressings in killing 160 chronic and burn wound microorganisms, including 29 strains of the superbug Methicillin-resistant Staphylococcus Aureus (MRSA).


Commenting on this announcement, Chris Meredith, Chief Executive Officer of AMS stated:


“We are very pleased with the efficacy results for our silver alginate woundcare products, which continue to prove effective against MRSA, one of the most problematic infections to treat. Our quality silver alginate products, coupled with supporting clinical evidence such as these latest studies, have helped our partners successfully capture 20% of the US$230 million global antimicrobial fibre market in the last five years. We look forward to continued success in this area.”


– ends –


For further enquiries:



Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer

Mary Tavener, Finance Director


+44 (0) 1606 545508

Tavistock Communications

John West / Chris Munden / Andrew Dunn


+44 (0) 20 7920 3150


Notes to Editors:


AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.


AMS’ wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.


This information is provided by RNS
The company news service from the London Stock Exchange